Strategic Signals Weekly

Atara Biotherapeutics announced that a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Complete Response Letter (CRL) issued on January 9, 2026, for the Biologics License Application (BLA) of EBVALLO™. This meeting is a critical step for the company to address the FDA's concerns and determine the next steps for the drug's potential approval.

Drug: EBVALLO™

Capricor Therapeutics announced that the FDA has lifted the Complete Response Letter (CRL) for its Biologics License Application (BLA) for Deramiocel. The FDA has resumed its review of the investigational cell therapy for Duchenne muscular dystrophy (DMD) cardiomyopathy. The BLA resubmission is classified as a Class 2, with a PDUFA target action date of August 22, 2026.

Drug: Deramiocel · Indication: Duchenne muscular dystrophy (DMD) cardiomyopathy

Capricor Therapeutics announced that the FDA has lifted the Complete Response Letter (CRL) for its Biologics License Application (BLA) for Deramiocel. The FDA has resumed its review of the investigational cell therapy for Duchenne muscular dystrophy (DMD) cardiomyopathy. The BLA resubmission is classified as a Class 2, with a PDUFA target action date of August 22, 2026.

Drug: Deramiocel · Indication: Duchenne muscular dystrophy (DMD) cardiomyopathy

Atara Biotherapeutics announced that a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Complete Response Letter (CRL) issued on January 9, 2026, for the Biologics License Application (BLA) of EBVALLO™. This meeting is a critical step for the company to address the FDA's concerns and determine the next steps for the drug's potential approval.

Xencor, Inc. received a notice of termination from Genentech, Inc. and F. Hoffmann-La Roche Ltd for their Amended and Restated Collaboration and License Agreement, effective September 4, 2026. Genentech elected to terminate the agreement for convenience after Roche removed efbalropendekin alfa, the sole active collaboration product, from its development pipeline in January 2025. Xencor had already ceased cost-sharing development activities for the product in the first half of 2024.

Drug: efbalropendekin alfa · Partner: Genentech, Inc. and F. Hoffmann-La Roche Ltd

Dianthus Therapeutics, Inc. announced a public equity offering, entering into an underwriting agreement with several firms including Jefferies LLC and TD Securities (USA) LLC. The company will issue and sell common stock and pre-funded warrants, with the underwriters fully exercising their option for additional shares. The offering is expected to generate approximately $673.5 million in net proceeds for the company.

Xenon Pharmaceuticals Inc. completed an underwritten public offering, raising approximately $707.7 million in net proceeds. The offering, which closed on March 12, 2026, included 12,236,843 common shares and pre-funded warrants to purchase an additional 877,194 common shares, with underwriters fully exercising their option for an additional 1,710,526 common shares.

Longeveron Inc. completed an initial closing of a private placement, raising approximately $15.9 million from institutional and accredited investors. A second closing for an additional $15.0 million is contingent on achieving statistically significant primary endpoints in a Phase 2b study of laromestrocel for Hypoplastic Left Heart Syndrome (HLHS) and a specific stock price threshold. The company intends to use the proceeds to fund the ongoing clinical and regulatory development of laromestrocel and expects current cash to fund operations into Q4 2026.

Prelude Therapeutics Incorporated previously entered into an Open Market Sale Agreement with Jefferies LLC to sell up to $75.0 million of its common stock. The company has now filed a prospectus supplement, allowing it to offer and sell an additional $25.0 million of common stock through Jefferies, bringing the total potential offering to $100.0 million. This financing is being conducted under its existing Shelf Registration Statement.

Lineage Cell Therapeutics, Inc. filed a prospectus supplement to offer and sell common shares with an aggregate offering price of up to $60,000,000 through B. Riley Securities, Inc. This at-the-market (ATM) offering is part of their existing shelf registration statement on Form S-3. This new offering is in addition to approximately $22.6 million in common shares already sold under prior supplements.